18F-氟脱氧葡萄糖摄取作为肝细胞癌索拉非尼治疗患者的预后预测指标
本研究为回顾性队列,纳入35例接受索拉非尼治疗至少30天、治疗前1个月内行18F-FDG PET/CT的BCLC-C期肝细胞癌患者。治疗前肿瘤与肝脏SUV比值(TLR)≥2.9组(17例)中位总生存3.7个月,TLR<2.9组(18例)为12.2个月(P<0.001),但两组疾病控制率无显著差异。多因素分析显示TLR≥2.9和Child-Pugh B级是总生存的不良预后因素,TLR≥2.9是唯一无进展生存的不良预后因素。
要点
- 治疗前TLR≥2.9的BCLC-C期肝细胞癌患者索拉非尼治疗后中位总生存3.7个月,TLR<2.9者为12.2个月(P<0.001)。
- 两组疾病控制率无显著差异,TLR可能不能预测肿瘤对索拉非尼的治疗反应。
- 多因素分析中TLR≥2.9(HR=6.318,P=0.002)和Child-Pugh B级(HR=4.316,P=0.044)是总生存的不良预后因素。
核心结论
- 治疗前18F-FDG PET评估的肿瘤代谢活性是接受索拉非尼单药治疗的BCLC-C期肝细胞癌患者生存的独立预后因素,但可能不能预测肿瘤对该治疗的反应。
研究设计与样本
- 回顾性队列研究,纳入接受索拉非尼治疗至少30天且在治疗前1个月内行18F-FDG PET/CT的肝细胞癌患者,共35例。
- 测量代谢最活跃病灶的肿瘤与肝脏标准化摄取值比值(TLR)进行统计分析。
主要发现
- 35例患者中,首次疗效评估时2例获部分缓解,11例为疾病稳定。
- TLR≥2.9组(17例)索拉非尼治疗后中位总生存3.7个月,TLR<2.9组(18例)中位总生存12.2个月(P<0.001)。
- 两组疾病控制率无显著差异。
- 多因素分析中,治疗前TLR≥2.9(HR=6.318,P=0.002)和Child-Pugh B级(HR=4.316,P=0.044)是总生存的不良预后因素。
- 多因素分析中,TLR≥2.9(HR=2.911,P=0.024)是无进展生存的唯一不良预后因素。
关键数值与推荐
- TLR阈值2.9:TLR≥2.9(n=17)中位总生存3.7个月 vs TLR<2.9(n=18)中位总生存12.2个月(P<0.001)。
- 总生存多因素分析:TLR≥2.9的HR=6.318(P=0.002),Child-Pugh B级的HR=4.316(P=0.044)。
- 无进展生存多因素分析:TLR≥2.9的HR=2.911(P=0.024)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sorafenib, an oral multikinase inhibitor, is a recommended treatment option available for patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). This study aimed to evaluate the performance of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) for predicting tumour progression during sorafenib treatment. METHODS: We formed a retrospective cohort comprising patients treated with sorafenib for at least 30 days and undergoing 18F-FDG PET/CT within 1 month before treatment. For statistical analyses, the tumour-to-liver standardised uptake value (SUV) ratio (TLR) of the most hypermetabolic lesion was measured. RESULTS: Among a total of 35 patients, two obtained partial remission, and 11 showed stable disease after the first response evaluation. Patients with a TLR ≥ 2.9 (n = 17) had a median overall survival (OS) of 3.7 months after sorafenib treatment, whereas patients with a TLR < 2.9 (n = 18) had median OS of 12.2 months (P < 0.001), although the disease control rate was not significantly different between the two groups. Pretreatment TLR ≥ 2.9 (hazard ratio [HR] = 6.318, P = 0.002) and Child-Pugh class B (HR = 4.316, P = 0.044) were poor prognostic factors for OS, and a TLR ≥ 2.9 (HR = 2.911, P = 0.024) was the only poor prognostic factor for progression-free survival in a multivariate analysis. CONCLUSION: Pretreatment tumour metabolic activity assessed by 18F-FDG PET is an independent prognostic factor for survival in patients with BCLC-C stage HCC receiving sorafenib monotherapy, although it may not predict tumour response to the treatment.
引用
- Sung PS, Park HL, Yang K, et al. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2017. PMID: 29124280. doi:10.1007/s00259-017-3871-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。